Answers are grounded in this paper and cite their sources.
Obesity increases the risk of several cancers through endocrine, metabolic, and inflammatory alterations. Diet influences these processes by shaping energy balance, adipose tissue function, insulin signaling, and interactions between the gut and peripheral organs. This narrative review examines how adipose tissue dysfunction supports tumor development and how nutritional interventions, physical activity, and incretin-based therapies may modify the underlying pathways. Particular attention is given to the insulin–insulin-like growth factor (IGF) axis, adipokines, nutrient sensing, and the context-dependent actions of muscle-derived interleukin-6. Evidence from human dietary studies does not establish a universal advantage of continuous restriction over intermittent regimens, and findings from animal tumor models require separate interpretation. Structured exercise has improved disease-free survival in a randomized trial after adjuvant chemotherapy for resected colon cancer. Incretin-based therapies produce substantial weight loss and selected cardiovascular benefits, whereas their effects on cancer incidence, recurrence, and survival remain incompletely established. Observational associations and experimental antitumor mechanisms should therefore inform prospective research rather than treatment claims. An integrated approach to obesity in oncology should address metabolic health while preserving nutritional adequacy, muscle mass, and treatment tolerance.
No takes yet. Share an insight, caveat, or question.
Maiorano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: